Focus: Ceribell is a medical device biotechnology company specializing in fast EEG (electroencephalogram) systems for rapid neurological diagnostics. The company focuses on point-of-care EEG solutions in acute care settings, particularly for delirium and seizure detection in ICU environments.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Cooling — net -6 jobs in 30d
21 added, 27 removed. Slower than typical.
Best suited for commercial/sales-focused professionals or device specialists seeking growth-stage opportunity in neurology diagnostics; less attractive for traditional pharma drug developers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core commercial product designed for rapid point-of-care EEG monitoring in ICU settings to detect delirium.
Help build intelligence for Ceribell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ceribell's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Focused solution for seizure detection, addressing critical diagnostic gaps in emergency neurology care.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles